Literature DB >> 20457926

Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.

Yongjun Sui1, Qing Zhu, Susan Gagnon, Amiran Dzutsev, Masaki Terabe, Monica Vaccari, David Venzon, Dennis Klinman, Warren Strober, Brian Kelsall, Genoveffa Franchini, Igor M Belyakov, Jay A Berzofsky.   

Abstract

Adjuvant effects on innate as well as adaptive immunity may be critical for inducing protection against mucosal HIV and simian immunodeficiency virus (SIV) exposure. We therefore studied effects of Toll-like receptor agonists and IL-15 as mucosal adjuvants on both innate and adaptive immunity in a peptide/poxvirus HIV/SIV mucosal vaccine in macaques, and made three critical observations regarding both innate and adaptive correlates of protection: (i) adjuvant-alone without vaccine antigen impacted the intrarectal SIVmac251 challenge outcome, correlating with surprisingly long-lived APOBEC3G (A3G)-mediated innate immunity; in addition, even among animals receiving vaccine with adjuvants, viral load correlated inversely with A3G levels; (ii) a surprising threshold-like effect existed for vaccine-induced adaptive immunity control of viral load, and only antigen-specific polyfunctional CD8(+) T cells correlated with protection, not tetramer(+) T cells, demonstrating the importance of T-cell quality; (iii) synergy was observed between Toll-like receptor agonists and IL-15 for driving adaptive responses through the up-regulation of IL-15Ralpha, which can present IL-15 in trans, as well as for driving the innate A3G response. Thus, strategic use of molecular adjuvants can provide better mucosal protection through induction of both innate and adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457926      PMCID: PMC2906837          DOI: 10.1073/pnas.0911932107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Anatomic site and immune function correlate with relative cytokine mRNA expression levels in lymphoid tissues of normal rhesus macaques.

Authors:  K Abel; M J Alegria-Hartman; K Zanotto; M B McChesney; M L Marthas; C J Miller
Journal:  Cytokine       Date:  2001-12-07       Impact factor: 3.861

2.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

3.  IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.

Authors:  SangKon Oh; Liyanage P Perera; Donald S Burke; Thomas A Waldmann; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

Review 4.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

5.  Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

Authors:  Qing Zhu; Colt Egelston; Susan Gagnon; Yongjun Sui; Igor M Belyakov; Dennis M Klinman; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

6.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.

Authors:  I M Belyakov; Z Hel; B Kelsall; V A Kuznetsov; J D Ahlers; J Nacsa; D I Watkins; T M Allen; A Sette; J Altman; R Woodward; P D Markham; J D Clements; G Franchini; W Strober; J A Berzofsky
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

7.  Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules.

Authors:  J L Dzuris; J Sidney; H Horton; R Correa; D Carter; R W Chesnut; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.

Authors:  L Jean Patterson; Nina Malkevitch; David Venzon; Joel Pinczewski; Victor Raúl Gómez-Román; Liqun Wang; V S Kalyanaraman; Phillip D Markham; Frank A Robey; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus.

Authors:  Marcin Kwissa; Rama R Amara; Harriet L Robinson; Bernard Moss; Sefik Alkan; Abdul Jabbar; Francois Villinger; Bali Pulendran
Journal:  J Exp Med       Date:  2007-10-22       Impact factor: 14.307

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  48 in total

Review 1.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

2.  Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.

Authors:  Rajesh Thippeshappa; Patricia Polacino; Monica T Yu Kimata; Edward B Siwak; David Anderson; Weiming Wang; Laura Sherwood; Reetakshi Arora; Michael Wen; Paul Zhou; Shiu-Lok Hu; Jason T Kimata
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 3.  The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise.

Authors:  Yegor Voronin; Amapola Manrique; Alan Bernstein
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 4.  Innate immunity in acute HIV-1 infection.

Authors:  Persephone Borrow
Journal:  Curr Opin HIV AIDS       Date:  2011-09       Impact factor: 4.283

5.  Vaccine-induced myeloid cell population dampens protective immunity to SIV.

Authors:  Yongjun Sui; Alison Hogg; Yichuan Wang; Blake Frey; Huifeng Yu; Zheng Xia; David Venzon; Katherine McKinnon; Jeremy Smedley; Mercy Gathuka; Dennis Klinman; Brandon F Keele; Sol Langermann; Linda Liu; Genoveffa Franchini; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

6.  Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.

Authors:  Saeed Nazeri; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Georges Snounou; Chiara Andolina; François Nosten
Journal:  Med Microbiol Immunol       Date:  2018-06-09       Impact factor: 3.402

Review 7.  A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.

Authors:  Jay A Berzofsky
Journal:  Vaccine       Date:  2011-11-21       Impact factor: 3.641

8.  Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution.

Authors:  Kimberly Schmitt; Kejun Guo; Malinda Algaier; Autumn Ruiz; Fang Cheng; Jianming Qiu; Silke Wissing; Mario L Santiago; Edward B Stephens
Journal:  Virology       Date:  2011-08-25       Impact factor: 3.616

Review 9.  The CD8 T-cell road to immunotherapy of toxoplasmosis.

Authors:  Rajarshi Bhadra; Jason P Gigley; Imtiaz A Khan
Journal:  Immunotherapy       Date:  2011-06       Impact factor: 4.196

Review 10.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.